328
N. Firth et al.
In conclusion, RPDs are an important area for fu-
ture study. Greater collaboration between pre-clinical
and clinical recovery scientists would increase the
rate of translation in this field (72). Development of
reporting standards for current trials and adherence to
recommendations from the stroke recovery research
community would significantly improve trial quality
(65). Increased methodological rigor is imperative to
allow comparison between recovery promoting drugs
in future, and will be achieved through stricter adhe-
rence to the Template for Intervention Description
and Replication (TIDieR) checklist and Consolidated
Standards of Reporting Trials (CONSORT) statement,
to adequately describe adjuvant rehabilitation interven-
tions and parallel group randomized trials, respectively
(73, 74). Considered attention to the limitations of past
RPD research may ultimately lead to discoveries with
the potential to impact the global disability burden of
stroke.
ACKNOWLEDGEMENTS
KSH is supported by a National Health and Medical Research
Council Early Career Fellowship (GNT1088449).
The Florey Institute of Neuroscience and Mental Health ack-
nowledges support from the Victorian Government and funding
from the Operational Infrastructure Support Grant.
The authors have no conflicts of interest to declare.
REFERENCES
1. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A,
Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5
hours after acute ischemic stroke. N Engl J Med 2008;
359: 1317–1329.
2. Lutsep HL, Clark WM. Neuroprotective agents in stroke:
overview of neuroprotective agents, prevention of early
ischemic injury, prevention of reperfusion injury. 2017
[cited 2017 Aug 24]. Available from: http://emedicine.
medscape.com/article/1161422–overview.
3. Cramer SC. An overview of therapies to promote repair
of the brain after stroke. Head Neck 2011; 33: S5–S7.
4. Hermann DM, Chopp M. Promoting neurological recovery
in the post-acute stroke phase: benefits and challenges.
Eur Neurol 2014; 72: 317–325.
5. Kalra L, Langhorne P. Facilitating recovery: evidence for
organized stroke care. J Rehabil Med 2007; 39: 97–102.
6. Bernhardt J, Chan J, Nicola I, Collier JM. Little therapy, little
physical activity: rehabilitation within the first 14 days of
organized stroke unit care. J Rehabil Med 2007; 39: 43–48.
7. Martinsson L, Hardemark H, Eksborg S. Amphetamines for
improving recovery after stroke. Cochrane Database Syst
Rev 2007: Cd002090.
8. Mead GE, Hsieh CF, Lee R, Kutlubaev MA, Claxton A,
Hankey GJ, et al. Selective serotonin reuptake inhibitors
(SSRIs) for stroke recovery. Cochrane Database Syst Rev
2012; 11: Cd009286.
9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC,
Ioannidis JPA, et al. The PRISMA Statement for Reporting
Systematic Reviews and Meta-Analyses of studies that
evaluate health care interventions: explanation and ela-
boration. PLoS Med 2009; 6: e1000100.
10. Bernhardt J, Hayward KS, Kwakkel G, Ward NS, Wolf SL,
www.medicaljournals.se/jrm
Borschmann K, et al. Agreed definitions and a shared vi-
sion for new standards in stroke recovery research: The
Stroke Recovery and Rehabilitation Roundtable taskforce.
Int J Stroke 2017; 12: 444–450.
11. World Health Organization. Towards a common language
for functioning, disability and health ICF. Geneva: World
Health Organization; 2002.
12. Higgins J, Green S, (editors). Cochrane Handbook for Sys-
tematic Reviews of Interventions Version 5.1.0 [updated
2011 Mar]: The Cochrane Collaboration 2011. Available
from: www.cochrane-handbook.org.
13. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D,
Oxman AD, et al. The Cochrane Collaboration’s tool for
assessing risk of bias in randomised trials. BMJ 2011;
343: d5928.
14. Centre for Evaluation and Monitoring. Effect size calcula-
tor – CEM: Durham University. 2017 [cited 2017 May].
Available from: http://www.cem.org/effect-size-calculator.
15. Acler M, Fiaschi A, Manganotti P. Long-term levodopa ad-
ministration in chronic stroke patients. A clinical and neu-
rophysiologic single-blind placebo-controlled cross-over
pilot study. Restor Neurol Neurosci 2009; 27: 277–283.
16. Floel A, Hummel F, Breitenstein C, Knecht S, Cohen LG.
Dopaminergic effects on encoding of a motor memory in
chronic stroke. Neurology 2005; 65: 472–474.
17. Gourab K, Schmit BD, Hornby TG. Increased lower limb
spasticity but not strength or function following a single-
dose serotonin reuptake inhibitor in chronic stroke. Arch
Phys Med Rehabil 2015; 96: 2112–2119.
18. Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A,
Manelfe C, et al. Fluoxetine modulates motor performance
and cerebral activation of patients recovering from stroke.
Ann Neurol 2001; 50: 718–729.
19. Restemeyer C, Weiller C, Liepert J. No effect of a levodopa
single dose on motor performance and motor excitabi-
lity in chronic stroke. A double-blind placebo-controlled
cross-over pilot study. Restor Neurol Neurosci 2007; 25:
143–150.
20. Rosser N, Heuschmann P, Wersching H, Breitenstein C,
Knecht S, Floel A. Levodopa improves procedural motor
learning in chronic stroke patients. Arch Phys Med Rehabil
2008; 89: 1633–1641.
21. Schambra HM, Martinez-Hernandez IE, Slane KJ, Boehme
AK, Marshall RS, Lazar RM. The neurophysiological effects
of single-dose theophylline in patients with chronic stroke:
a double-blind, placebo-controlled, randomized cross-over
study. Restor Neurol Neurosci 2016; 34: 799–813.
22. Tardy J, Pariente J, Leger A, Dechaumont-Palacin S,
Gerdelat A, Guiraud V, et al. Methylphenidate modulates
cerebral post-stroke reorganization. NeuroImage 2006;
33: 913–922.
23. Zittel S, Weiller C, Liepert J. Reboxetine improves motor
function in chronic stroke. J Neurol 2007; 254: 197–201.
24. Zittel S, Weiller C, Liepert J. Citalopram improves dexterity
in chronic stroke patients. Neurorehabil Neural Repair
2008; 22: 311–314.
25. Cherry KM, Lenze EJ, Lang CE. Combining d-cycloserine
with motor training does not result in improved general
motor learning in neurologically intact people or in people
with stroke. J Neurophysiol 2014; 111: 2516–2524.
26. Crisostomo EA, Duncan PW, Propst M, Dawson DV, Davis
JN. Evidence that amphetamine with physical therapy
promotes recovery of motor function in stroke patients.
Ann Neurol 1988; 23: 94–97.
27. Sonde L, Nordström M, Nilsson CG, Lökk J, Viitanen M.
A double-blind placebo-controlled study of the effects of
amphetamine and physiotherapy after stroke. Cerebrovasc
Dis 2001; 12: 253–257.
28. Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani
M, et al. Effects of fluoxetine and maprotiline on functional
recovery in poststroke hemiplegic patients undergoing
rehabilitation therapy. Stroke 1996; 27: 1211–1214.
29. Lokk J, Roghani RS, Delbari A. Effect of methylphenidate